Digital Patient Profile Catalog set to fast-track oncology clinical development
With cancer accounting for nearly 10 million deaths in 2020 and 28 million new cases of cancer expected every year by 2040, the speed at which new treatments reach patients must accelerate.
We published the first edition of our Digital Patient Profile catalog last week, to give the industry access to a granular breakdown of patient populations for 28 key disease indications, derived from analysis of patient data in the industry’s largest clinical trial database. This includes 11 oncology indications and other prevalent diseases including Alzheimer’s, COVID-19 and Crohn’s disease.
Resilience to external events
The clinical development sector is highly sensitive to external events for two main reasons. One, because of the many moving parts involved – from patients, clinicians, sponsors, regulators and supply chain partners. And two, the fact that it is global in nature – often involving people and materials from many different countries and regions. In the end, we want our innovative medicines to benefit all patients, regardless of where they reside.
Almost one in five clinical trials recruit only a single patient. How can the industry tackle this issue?
Before heading to SCOPE 2023 this month, we released our latest analysis investigating enrollment data from 173 cancer clinical trials over the last three years. Our analysis uncovered chronic challenges in clinical development, finding that 2,298 of 11,826 investigator sites (nearly one in five) have only enrolled a single patient.
Collagen Clinical Development: Beyond Cosmetics
As the most abundant protein in the human body and a crucial component of connective tissue, collagen is crucial for the body’s strength and structure. However, part of the natural aging process is collagen depletion. Today, scientists around the world are investigating how collagen can help to mitigate age-related conditions. The past decade has witnessed a growing interest in how collagen-based therapies could treat diseases, prevent complications, and benefit the health of aging people.
To improve patient centricity in clinical development, we need to move past ‘gut-feeling’ and towards a data-led approach
Clinical development has faced several years of disruption from recent global events, from the pandemic to the ongoing war in Ukraine and now a looming economic crisis. Given the scale of such events, it’s more important than ever to be able to accurately predict outcomes for clinical trials and minimize patient burden and R&D costs. This requires moving from a perception-led approach to a data-led approach. It means learning from the past and present by simulating the future. And designing smarter trials that lead to faster cures.